Oncotelic Therapeutics (OTCQB: OTLC) announced that Chief Business Officer Saran Saund will deliver the opening keynote on the second day of the 22nd Drug Discovery Strategic Summit on Oct. 22, 2026, at 9 a.m. Pacific Time in Millbrae, California. The presentation will explore partition and aggregation as an organizing principle for AI-enabled drug discovery, emphasizing how complex research questions can be divided into focused investigations and findings combined to develop testable hypotheses.
Saund will discuss the company's proprietary PDAOAI platform, which indexes approximately 29 million PubMed abstracts, along with its international intellectual property strategy, planned expansion into genetic discovery and Fastbot/Membot technology designed to make AI-powered research accessible to individual investigators. The keynote comes as drug discovery increasingly relies on computational tools to manage vast scientific literature and generate actionable insights.
The PDAOAI platform's indexing of roughly 29 million PubMed abstracts represents a significant scale of biomedical literature, and the company's planned expansion into genetic discovery and Fastbot/Membot technology could broaden access to AI-powered research beyond large institutions. For investors, the presentation offers visibility into Oncotelic's AI strategy and intellectual property positioning. To view the full press release, visit https://nnw.fm/O1lLk.
Oncotelic Therapeutics develops oncology and immunotherapy products, with a focus on cancers with substantial unmet needs and rare pediatric indications. The company also develops the PDAOAI platform to support its work in drug discovery and development. The latest news and updates relating to OTLC are available in the company's newsroom at https://nnw.fm/OTLC.
The announcement was distributed through NetworkNewsWire, a specialized communications platform focused on financial news and content distribution for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio at IBN that delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution and tailored corporate communications solutions.
For readers following AI in biotech, the keynote could signal how smaller players are positioning proprietary platforms and intellectual property in a competitive field. Full terms of use and disclaimers are available at https://www.NetworkNewsWire.com/Disclaimer.
